MOVENTIG (naloxegol), peripheral opioid receptor antagonist laxative
GASTROENTEROLOGY - New medicinal product
Opinions on drugs - Posted on Mar 14 2016
Reason for request
No clinical benefit demonstrated in the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxatives.
- MOVENTIG has Marketing Authorisation in the treatment of opioid-induced constipation in adults who have had an inadequate response to laxatives.
- After 12 weeks of treatment, the effect size in favour of naloxegol 12.5 mg/day and 25 mg/day was modest versus placebo and the efficacy at the daily dose of 12.5 mg/day was poorly established in patients with non-cancer pain.
- Efficacy and safety have not been assessed in patients with cancer pain.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments